The Alpha 1 antitrypsin deficiency - etiology, symptoms in various organs, diagnosis, treatment, prognosis
DOI:
https://doi.org/10.12775/JEHS.2024.61.013Keywords
alpha1-antitrypsin, alpha-1-antitrypsine deficiency, COPD, cirrhosisAbstract
Introduction:
Alpha-1 antitrypsin (AAT) is a glycoprotein produced by liver, belonging to the serine protease inhibitor family. Alpha-1 antitrypsin deficiency (AATD) is very common autosomal recessive genetic disease caused by point mutation in SERPINA1 gene. Mutations in the alpha-1 antitrypsin gene lead to production of misfolded AAT resulting in impaired release into the blood. This disorder leads to destruction of connecting tissue especially in lungs and to accumulation of retarded protein in the liver.
Purpose:
Most studies addressing AAT deficiency focus on presenting symptoms related to the lungs and liver. We want to take a broader look at this issue, so we have closely examined scientific reports on the presentation of the disease in organs other than the lungs and liver. The goal is to gather holistic knowledge about the disease to enhance awareness and treatment.
Material and methods:
In our paper, we endeavored to address the issue of AAT deficiency comprehensively. We explored symptoms with an emphasis on organs beyond the liver and lungs. We also delved into the etiology, diagnosis, treatment, and prognosis of this disease.
Discussion:
The clinical symptoms of alpha 1 antitrypsin deficiency extending beyond the liver and lungs remain inadequately described. We know that AAT deficiency can lead to excessive destruction of connective tissue in any organ, not just the lungs and liver. Unfortunately, this condition continues to go undiagnosed, and the number of scientific publications on symptoms from other organs is too limited. This affects the insufficient attention given by doctors to tissue destruction in organs other than the lungs and liver.
References
Strnad P, McElvaney NG, Lomas DA. Alpha 1 -Antitrypsin Deficiency. Longo DL, editor. N Engl J Med. 2020 Apr 9;382(15):1443–55.
Stoller JK, Aboussouan LS. A Review of α 1 -Antitrypsin Deficiency. Am J Respir Crit Care Med. 2012 Feb 1;185(3):246–59.
Köhnlein T, Welte T. Alpha-1 Antitrypsin Deficiency: Pathogenesis, Clinical Presentation, Diagnosis, and Treatment. The American Journal of Medicine. 2008 Jan;121(1):3–9.
Valiulis A, Utkus A, Stukas R, Valiulis A, Siderius L, Leonardo da Vinci Alfa-1-Qual No. LLP-LdV-PRT-2011-LT-0300 project group. Introducing standards of the best medical practice for patients with inherited alpha-1-antitrypsin deficiency in Central Eastern Europe. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014;35(1):107–14.
Mornex JF. [Alpha-1 antitrypsin deficiency 50 years later]. Bull Acad Natl Med. 2014;198(4–5):757–66.
Edgar R, Patel M, Bayliss S, Crossley D, Sapey E, Turner A. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. COPD. 2017 May;Volume 12:1295–308.
Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, et al. Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514–24.
Lachaux A, Dumortier J. Atteinte hépatique du déficit héréditaire en alpha-1-antitrypsine. Revue des Maladies Respiratoires. 2014 Apr;31(4):357–64.
Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Airways Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2016 Sep 20 [cited 2024 Jan 23];2016(9). Available from: http://doi.wiley.com/10.1002/14651858.CD007851.pub3
Patel D, Teckman JH. Alpha-1-Antitrypsin Deficiency Liver Disease. Clinics in Liver Disease. 2018 Nov;22(4):643–55.
Bouchecareilh M. Le déficit en alpha-1-antitrypsine. Med Sci (Paris). 2014 Oct;30(10):889–95.
Duvoix A, Roussel BD, Lomas DA. Molecular pathogenesis of alpha-1-antitrypsin deficiency. Revue des Maladies Respiratoires. 2014 Dec;31(10):992–1002.
Stoller JK, Aboussouan LS. A Review of α 1 -Antitrypsin Deficiency. Am J Respir Crit Care Med. 2012 Feb 1;185(3):246–59.
Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008 Dec;3(1):16.
Stoller JK, Aboussouan LS. α1-antitrypsin deficiency. The Lancet. 2005 Jun;365(9478):2225–36.
Nuñez A, Barrecheguren M, Rodríguez E, Miravitlles M, Esquinas C. Diagnosis of alpha1-antitrypsin deficiency not just in severe COPD. Pulmonology. 2018 Nov;24(6):351–3.
Teckman JH. Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2013 Mar 7;10(sup1):35–43.
Deshayes S, Martin Silva N, Grandhomme F, Khoy K, Mariotte D, Boutemy J, et al. Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody–associated Vasculitis: Results from a French Retrospective Monocentric Cohort. J Rheumatol. 2019 Nov;46(11):1502–8.
Henao MP, Craig TJ. Understanding alpha-1 antitrypsin deficiency: A review with an allergist’s outlook. allergy asthma proc. 2017 Mar 1;38(2):98–107.
Balduyck M, Odou MF, Zerimech F, Porchet N, Lafitte JJ, Maitre B. Diagnosis of alpha-1 antitrypsin deficiency: Modalities, indications and diagnosis strategy. Revue des Maladies Respiratoires. 2014 Oct;31(8):729–45.
Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and Management of Patients With α1-Antitrypsin (A1AT) Deficiency. Clinical Gastroenterology and Hepatology. 2012 Jun;10(6):575–80.
Santangelo S, Scarlata S, Poeta M, Bialas A, Paone G, Incalzi R. Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches. CMC. 2017 Jan 16;24(1):65–90.
Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, et al. Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology. 2020 Mar;25(3):321–35.
Brantly M. Treatment for Alpha-1 Antitrypsin Deficiency: Does Augmentation Therapy Work? Am J Respir Crit Care Med. 2023 Nov 1;208(9):948–9.
Strange C. Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy. Respir Care. 2018 Jun;63(6):690–8.
Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res. 2017 Dec;18(1):105.
Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood). 2010 Jun;235(6):700–9.
Jaspers E, Van Dijck I, Hoffman I, Knops N, Stéphenne X, Witters P, et al. Cystic fibrosis and alpha-1 antitrypsin deficiency: case report and review of literature. BMC Pediatr. 2022 Dec;22(1):247.
Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update. Br J Dermatol. 2016 Apr;174(4):753–62.
Valverde R, Rosales B, Ortiz-de Frutos FJ, Rodríguez-Peralto JL, Ortiz-Romero PL. Alpha-1-Antitrypsin Deficiency Panniculitis. Dermatologic Clinics. 2008 Oct;26(4):447–51.
Smith KC, Pittelkow MR, Su WP. Panniculitis associated with severe alpha 1-antitrypsin deficiency. Treatment and review of the literature. Arch Dermatol. 1987 Dec;123(12):1655–61.
Al-Niaimi F, Lyon C. Severe ulcerative panniculitis caused by alpha 1-antitrypsin deficiency: Remission induced and maintained with intravenous alpha 1-antitrypsin. Journal of the American Academy of Dermatology. 2011 Jul;65(1):227–9.
O’Riordan K, Blei A, Rao MS, Abecassis M. ??1-ANTITRYPSIN DEFICIENCY-ASSOCIATED PANNICULITIS: Resolution with Intravenous ??1-Antitrypsin Administration and Liver Transplantation. Transplantation. 1997 Feb;63(3):480–2.
Lipsker D, Perrigouard C, Foubert A, Cribier B. Anakinra for Difficult-to-Treat Neutrophilic Panniculitis: IL-1 Blockade as a Promising Treatment Option for Neutrophil-Mediated Inflammatory Skin Disease. Dermatology. 2010;220(3):264–7.
Dawkins P, Wood A, Nightingale P, Stockley R. Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. Respiratory Medicine. 2009 Oct;103(10):1540–7.
Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine. 2014 Feb;20(2):105–15.
Geraminejad P, DeBloom JR, Walling HW, Sontheimer RD, VanBeek M. Alpha-1-antitrypsin associated panniculitis: The MS variant. Journal of the American Academy of Dermatology. 2004 Oct;51(4):645–55.
Perlmutter D. Alpha-1-Antitrypsin Deficiency. Semin Liver Dis. 1998;18(03):217–25.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Dawid Kościołek, Michał Urbaś, Martyna Kępczyk, Aleksandra Kościołek, Kaja Surowiecka, Jakub Misiak, Miłosz Ojdana, Konrad Szalbot, Mikołaj Tokarski, Natalia Marczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 269
Number of citations: 0